API Holdings, PharmEasy’s parent company, saw its valuation drop to $458 million—a 92% decrease from its $5.6 billion peak in 2021. Investor Janus Henderson slashed its valuation by 91.8%. PharmEasy has been struggling with debt repayment and delayed its IPO plans amid market challenges.